1Poole-Wilson PA, Swedberg K, Cleland JQ, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET) : randomised controlled trial[J]. Lancet,2003,362(2):7- 13.
2Frantz RP, Olson LJ, Grill D, et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure[J]. Am Heart J,2005,149(3) :541 - 547.
3Lysko PG, Webb CL, Gu JL. A comparison of Carvedilol and metoprolol antioxidant activities in vitro [ J ]. J cardiovasc pharmacol, 2000, 36 (2) : 277 - 281.
4Nagatomo Y, Yoshikawa T, Kohno T. Effects of beta-blocker therapy on high sensitivity c-reactive protein, oxidative stress, and cardiac function in patients with congestive heart failure[J]. J Card Fail, 2007,13 (5): 365 - 371.
5Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease[J]? Semin Nephrol, 2007,27(2): 555 - 564.
6Horani MH, Haas MJ, Mooradian AD. Suppression of Hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol [J]. Am J Ther,2006,13( 1 ) :2 - 7.
